Business Description
Sangamo Therapeutics Inc
NAICS : 325414
SIC : 2836
ISIN : US8006771062
Total Employee Number:
142Description
Sangamo Therapeutics Inc. is a clinical-stage genomic medicine company based in the United States. It develops engineered zinc finger proteins and other gene-editing and gene-regulation technologies to create treatments for serious genetic and neurological diseases. Its pipeline spans epigenetic regulation therapies, engineered adeno-associated virus (AAV) capsids for targeted delivery to the central nervous system, and gene therapies for conditions such as Fabry disease, hemophilia A, and neurological disorders including prion disease, tauopathies, ALS/FTD, and Huntington's disease. Sangamo also pursues ex vivo cell therapy programs, including CAR-Treg approaches for autoimmune and inflammatory conditions. The company generates revenue primarily through collaboration and license agreements with pharmaceutical partners, including milestone payments and royalties, alongside research funding, rather than from marketed products, as it has no approved medicines. Its activities are concentrated in the United States, with partnerships extending to international biopharmaceutical collaborators.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1.43 | |||||
Equity-to-Asset | -0.32 | |||||
Debt-to-Equity | -1.02 | |||||
Debt-to-EBITDA | -0.19 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 1/9 | |||||
Altman Z-Score | -44.82 | |||||
Beneish M-Score | -3.15 | |||||
WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -42 | |||||
3-Year EBITDA Growth Rate | 32.6 | |||||
3-Year EPS without NRI Growth Rate | 32 | |||||
3-Year FCF Growth Rate | 39.7 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 88.71 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-1 Month Momentum % | -8.93 | |||||
6-1 Month Momentum % | -57.03 | |||||
12-1 Month Momentum % | -71 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.7 | |||||
Quick Ratio | 0.7 | |||||
Cash Ratio | 0.52 | |||||
Days Sales Outstanding | 5.29 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -28.1 | |||||
Shareholder Yield % | -139.9 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -319.25 | |||||
Net Margin % | -356.89 | |||||
EBITDA Margin % | -300.28 | |||||
FCF Margin % | -261.76 | |||||
OCF Margin % | -261.43 | |||||
ROA % | -157.28 | |||||
ROIC % | -185.4 | |||||
3-Year ROIIC % | -31.75 | |||||
ROC (Joel Greenblatt) % | -458.96 | |||||
ROCE % | -369.88 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 1.17 | |||||
EV-to-EBIT | -0.47 | |||||
EV-to-EBITDA | -0.5 | |||||
EV-to-Forward-EBITDA | -2.4 | |||||
EV-to-Revenue | 1.5 | |||||
EV-to-Forward-Revenue | 0.34 | |||||
EV-to-FCF | -0.59 | |||||
Price-to-GF-Value | 0.01 | |||||
Price-to-Median-PS-Value | 0.11 | |||||
Earnings Yield (Greenblatt) % | -214.33 | |||||
FCF Yield % | -150.51 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Sangamo Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 34.557 | ||
| EPS (TTM) ($) | -0.383 | ||
| Beta | 0.0838 | ||
| 3-Year Sharpe Ratio | 0.39 | ||
| 3-Year Sortino Ratio | 0.78 | ||
| Volatility % | 195.5 | ||
| 14-Day RSI | - | ||
| 14-Day ATR ($) | 15.437711 | ||
| 20-Day SMA ($) | 15.5 | ||
| 12-1 Month Momentum % | -71 | ||
| 52-Week Range ($) | 0.03 - 0.7645 | ||
| Shares Outstanding (Mil) | 414.29 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Sangamo Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Sangamo Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-06 08:30 | In 46 days | ||
| Third quarter earnings results for 2026 | 2026-11-06 | In 45 days | ||
| Second quarter earnings conference call for 2026 | 2026-09-18 16:30 | -- | ||
| General meeting for 2026 | 2026-09-18 09:00 | -- | ||
| Second quarter earnings results for 2026 | 2026-09-18 | -- | ||
| First quarter earnings conference call for 2026 | 2026-05-14 16:30 | -- | ||
| First quarter earnings results for 2026 | 2026-05-14 | -- | ||
| Fourth quarter earnings conference call for 2025 | 2026-03-30 16:30 | -- | ||
| Annual report for 2025 | 2026-03-30 | -- | ||
| Fourth quarter earnings results for 2025 | 2026-03-30 | -- |
Show
Entries
Sangamo Therapeutics Inc Frequently Asked Questions
What is Sangamo Therapeutics Inc(LTS:0R1D)'s stock price today?
The current price of LTS:0R1D is $0.14. The 52 week high of LTS:0R1D is $0.76 and 52 week low is $0.03.
When is next earnings date of Sangamo Therapeutics Inc(LTS:0R1D)?
The next earnings date of Sangamo Therapeutics Inc(LTS:0R1D) is 2026-11-06 Est..
Does Sangamo Therapeutics Inc(LTS:0R1D) pay dividends? If so, how much?
Sangamo Therapeutics Inc(LTS:0R1D) does not pay dividend.
Press Release
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers